Overview

A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy

Status:
Unknown status

Trial end date:
2017-04-01

Target enrollment:

Participant gender:

Summary

This aim of study is to evaluate the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy by a randomized, double-blind, placebo-controlled trial.

Phase:

Phase 2

Details

Lead Sponsor:

Korean South West Oncology Group

Treatments:

Olanzapine